Cytek Biosciences, a provider of cell analysis instrumentation and solutions, has closed a $120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating.

Cytek Biosciences is a leading flow cytometry solution provider that provides compact, affordable instruments with high multiplexing capability and a wide range of services to support researchers and clinicians. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe.